Medical device maker Boston Scientific (NYSE:BSX) has been a shocking success this year for investors, as its stock has jumped more than 80% year-to-date. Those are gains any investor can appreciate, but Boston's success hasn't come alongside its results.
Boston posted a solid second quarter that impressed Wall Street, but the company's still working on turning around from a lackluster past few years. The company's first-half sales fell year-over-year this year, mainly due to interventional cardiology and cardiac rhythm management businesses that have struggled to grow.
But Boston's outlook isn't bleak. The company just scored a big approval from the Food and Drug Administration in its small but growing electrophysiology business, and this segment has shown strong performance recently. Is Boston Scientific back on the path to success? Fool contributor Dan Carroll tells you all about this company's fortunes -- and what you can expect going forward -- in the video below.